ContraFect Corp represents a strong commitment to innovation, integrity, and scientific excellence. As a company specializing in the development of novel therapeutic products, ContraFect Corp follows a philosophy focused on advancing breakthrough treatments for life-threatening infections. With an emphasis on addressing the growing challenges of antibiotic resistance, ContraFect Corp diligently follows rigorous research and development processes to deliver meaningful solutions for patients and healthcare providers. By continuously striving to improve patient outcomes and transform the way infectious diseases are treated, ContraFect Corp sets itself apart as a dedicated and forward-thinking leader in the industry.

ContraFect Corp primarily operates in the United States.

ContraFect Corp has achieved several significant milestones. The company successfully completed a Phase 2 clinical trial for its investigational drug candidate, CF-301, which showed promising results in treating Staphylococcus aureus bacteremia. ContraFect also received a Fast Track designation from the FDA for this drug candidate, highlighting its potential to address an unmet medical need. Additionally, the company initiated a Phase 3 clinical trial for CF-301, aiming to further evaluate its efficacy and safety. ContraFect Corp's achievements demonstrate its dedication to developing innovative therapies for serious and life-threatening infectious diseases.

ContraFect Corp is a biotechnology company that focuses on the discovery and development of novel therapies for life-threatening bacterial infections. Established in 2008, ContraFect Corp has been providing innovative solutions to the global healthcare industry. With a strong emphasis on researching and engineering antibodies, this company aims to combat the growing issue of antibiotic resistance. ContraFect Corp has achieved significant milestones, including the completion of successful clinical trials and the continued advancement of its product pipeline. By harnessing cutting-edge technology and a dedicated team, ContraFect Corp strives to revolutionize the treatment of serious infectious diseases.

The main competitors of ContraFect Corp in the market include biotechnology companies such as Achaogen Inc., AmpliPhi Biosciences Corporation, Aridis Pharmaceuticals LLC, and Novabay Pharmaceuticals Inc. These companies also specialize in developing novel therapies targeted at treating infectious diseases. However, ContraFect Corp distinguishes itself through its proprietary technology platform, lysin therapy, which has shown promise in addressing drug-resistant infections. With its innovative approach and focus on combating antibiotic resistance, ContraFect Corp has built a strong position in the market, setting itself apart from its competitors.

ContraFect Corp primarily operates in the biotechnology industry. This New York-based company focuses on the development and commercialization of innovative therapies to combat drug-resistant infections. With its proprietary lysin-based technology, ContraFect Corp targets serious bacterial and viral diseases, aiming to address unmet medical needs. As a pioneer in the field of lysins, ContraFect Corp aims to revolutionize the treatment landscape by providing potential alternatives to traditional antibiotics. By leveraging its expertise, research capabilities, and diversified pipeline, ContraFect Corp actively contributes to advancements in biotechnology, making it a prominent player in the industry.

The business model of ContraFect Corp revolves around developing and commercializing novel therapies to combat drug-resistant bacterial infections. As a biopharmaceutical company, ContraFect Corp focuses on creating innovative therapeutic proteins called lysins. These lysins are designed to selectively target and eliminate harmful bacteria, particularly those that have become resistant to traditional antibiotics. By utilizing a unique approach, ContraFect Corp aims to provide effective treatment options for patients suffering from serious and life-threatening infections. With their dedication to research and development, ContraFect Corp works towards addressing the urgent need for new solutions in the field of infectious diseases.

ContraFect P/E suhe on −0,00.

ContraFect KUV on 0.

AlleAktien kvaliteediskoor ettevõttele ContraFect on 6/10.

Praegu ei saa ContraFect käivet arvutada.

oodatud ContraFect kasum on −60,18 mln. USD.

ContraFect Corp is a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of severe bacterial and viral infections. The company works closely with leading experts in the field of infectious diseases to develop innovative therapies that address patients' medical needs. The business model of ContraFect is focused on three main areas: clinical development, product research, and business optimization. Within clinical development, the company conducts tests to evaluate the safety and efficacy of its therapeutics and bring them for approval by regulatory authorities. As part of product research, ContraFect identifies new targets and mechanisms of action to develop innovative therapies targeting bacteria and viruses. Finally, business optimization focuses on optimizing the launch, distribution, and marketing of therapeutics to provide the greatest benefit to patients and the company's shareholders. The company has developed a range of therapeutics that are currently in various stages of clinical development. These therapeutics include recombinant proteins, monoclonal antibodies, and peptides that target various bacteria and viruses such as MRSA, Pseudomonas aeruginosa, and influenza. ContraFect's flagship product CF-301 is a recombinant protein targeting Staphylococcus aureus and is currently being tested in Phase 2 of clinical development. The company has also developed a platform technology called Lysin, which focuses on peptides that target bacteria. Lysins are peptides that specifically kill bacteria by destroying their cell walls, setting them apart from conventional antibiotics. The company already has several Lysins in various stages of clinical development. ContraFect is also committed to establishing significant partnerships with other companies to expand its research and development activities and strengthen its product pipeline. In June 2020, the company announced a partnership with the Mayo Clinic to jointly develop a Lysin against Clostridioides difficile. ContraFect's business model is based on a strong research and development infrastructure that enables the company to develop innovative therapeutics that have the potential to effectively combat bacteria and viruses more than conventional antibiotics and antivirals. The company also aims to establish partnerships to expand its research and development activities and enhance its market launch options. With a growing product pipeline and a strong commitment to improving treatment options for patients with infectious diseases, ContraFect has a promising future ahead.

ContraFect maksab dividendi 0 USD, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu ContraFect jaoks arvutada või ettevõte ei maksa dividende välja.

ContraFect ISIN on US2123263004.

ContraFect WKN on A2PZKK.

ContraFect tähis on CFRX.

Viimase 12 kuu jooksul maksis ContraFect dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab ContraFect tõenäoliselt dividendi summas 0 USD.

ContraFect praegune dividenditootlus on .

ContraFect maksab kvartaalset dividendi. See makstakse välja kuudel .

ContraFect maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 USD. See vastab dividenditootlusele 0 %.

ContraFect on liigitatud sektorisse 'Tervis'.

Viimase ContraFect dividendide saamiseks 16.11.2024 suuruses 0 USD pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 16.11.2024.

Viimane dividendimakse toimus 16.11.2024.

Aastal 2023 maksis ContraFect 0 USD dividende.

ContraFect dividendid makstakse välja USD.